rna
engin
nanotechnolog
medic
applic
excit
emerg
research
field
rna
intrins
defin
featur
nanometr
scale
particularli
interest
candid
applic
due
amaz
divers
flexibl
versatil
structur
function
specif
current
use
sirna
silenc
target
gene
involv
diseas
gener
much
excit
scientif
commun
intrins
abil
sequencespecif
downregul
gene
express
temporallyand
spatial
control
fashion
led
heighten
interest
rapid
develop
sirnabas
therapeut
although
method
gene
silenc
achiev
high
efficaci
specif
vitro
effect
deliveri
nucleic
acid
specif
cell
vivo
hurdl
rna
therapeut
articl
cover
differ
rnabas
approach
diagnosi
prevent
treatment
human
diseas
focu
latest
develop
nonvir
carrier
sirna
deliveri
vivo
applic
challeng
sirna
therapi
well
potenti
solut
problem
approach
use
prnabas
vector
polyval
vehicl
specif
deliveri
sirna
ribozym
drug
therapeut
agent
specif
cell
therapi
also
address
cation
one
research
area
emerg
popular
field
nanotechnolog
involv
modif
engin
andor
assembl
organis
materi
nanometr
scale
therebi
form
conjug
altern
supramolecular
structur
modifi
materi
use
build
block
nanomedicin
nanotechnolog
biolog
macromolecul
includ
dna
rna
protein
intrins
defin
featur
nanometr
scale
serv
uniqu
power
build
block
bottomup
fabric
nanostructur
nanodevic
rna
particularli
interest
candid
nanotechnolog
applic
due
amaz
divers
flexibl
versatil
structur
function
rna
molecul
polym
made
four
nucleotid
u
g
c
thu
nt
rna
polym
gener
mani
differ
rna
molecul
threedimension
rna
structur
nanometr
scale
henc
construct
rna
nanoparticl
feasibl
bottomup
approach
exampl
one
earli
applic
rna
bottomup
assembl
construct
micrometrescal
rna
array
deriv
bacteriophag
motor
prna
detail
prnabas
nanostructur
pleas
see
ref
rna
molecul
design
manipul
level
simplic
characterist
dna
possess
flexibl
structur
function
similar
protein
exampl
ribozym
compos
rna
enzymat
properti
protein
likewis
rna
aptam
similar
antibodi
bind
small
molecul
specif
biosens
target
moieti
addit
pure
nanotechnolog
applic
rna
idea
silenc
target
gene
involv
diseas
use
nanos
therapeut
rna
gener
much
excit
scientif
commun
particular
mechan
rna
interfer
rnai
prompt
develop
sever
therapeut
strategi
rnai
sequencespecif
genesilenc
mechan
typic
involv
short
doublestrand
rna
dsrna
call
small
interf
rna
sirna
intrins
abil
sequencespecif
downregul
gene
express
temporallyand
spatial
control
fashion
led
heighten
interest
rapid
develop
sirnabas
therapeut
although
method
gene
silenc
high
efficaci
specif
achiev
vitro
effect
deliveri
nucleic
acid
specif
cell
vivo
hurdl
rna
therapeut
review
differ
rnabas
approach
diagnosi
prevent
treatment
human
diseas
articl
extens
earlier
public
time
focuss
latest
develop
nonvir
carrier
sirna
deliveri
vivo
applic
challeng
sirna
therapi
well
potenti
solut
problem
also
discuss
approach
use
prnabas
vector
polyval
vehicl
specif
deliveri
sirna
ribozym
drug
therapeut
agent
specif
cell
therapi
also
address
rna
molecul
potenti
diagnosi
prevent
treatment
human
diseas
follow
decod
human
genom
new
era
open
develop
new
gene
therapi
strategi
employ
nucleic
acid
ration
design
rna
sequenc
specif
block
express
select
gene
respons
variou
diseas
includ
cancer
viral
infect
genet
diseas
receiv
major
attent
recent
year
research
area
fuell
idea
select
specif
inhibit
tumour
growth
minim
side
effect
normal
cell
achiev
use
rna
simplic
rna
engin
combin
versatil
structur
function
highlight
use
nucleic
acidand
rnabas
strategi
therapi
next
list
sever
rnabas
therapeut
approach
ribozym
catalyt
rna
molecul
capac
bind
cleav
rna
molecul
intercept
cleav
messeng
rna
viral
genom
rna
ribozym
capabl
regul
gene
function
therapeut
purpos
structur
variabl
ribozym
translat
function
versatil
divers
hammerhead
ribozym
hairpin
ribozym
prna
classifi
small
ribozym
wherea
larger
ribozym
includ
intron
rnase
p
incorpor
escort
prna
activ
ribozym
enhanc
due
improv
fold
stabil
antisens
rna
singlestrand
nucleic
acid
oligom
inhibit
translat
watsoncrick
base
pair
target
mrna
sequenc
steric
block
translat
oligonucleotid
sequenc
coin
antisens
often
transcrib
direct
opposit
target
rna
dna
transcript
antisens
strand
bind
target
mrna
complementari
nearli
complementari
rna
strand
form
stabl
easili
detect
complex
use
probe
rnarna
interact
oligonucleotidebas
therapeut
current
market
fomivirsen
vitraven
isi
pharmaceuticalsnovarti
antisens
therapeut
target
cytomegaloviru
cmv
retin
aid
patient
rna
interfer
rnai
posttranscript
genesilenc
ptg
mechan
found
plant
invertebr
mammalian
cell
rnai
exist
sever
form
two
sirna
mirna
see
section
titl
aptam
discuss
articl
use
rnai
technolog
function
genom
highlight
systemat
rnaibas
genet
screen
c
eleg
drosophila
baulcomb
hamilton
found
cell
control
protein
product
novel
mechan
small
doublestrand
rna
molecul
bind
specif
mrna
sequenc
block
respect
gene
protein
express
furthermor
addit
aspect
rnai
recognis
past
year
elbashir
et
al
demonstr
rnai
mediat
sirna
cultur
mammalian
cell
andrew
z
fire
craig
c
mello
award
nobel
prize
physiolog
medicin
fundament
work
rnai
therapeut
potenti
sirna
key
molecul
rnai
pathway
sirna
short
usual
dsrna
strand
nt
overhang
cytoplasm
sirna
load
protein
complex
call
rnainduc
silenc
complex
risc
load
risc
complex
scan
intracellular
mrna
target
mrna
complementari
sequenc
load
sirna
target
mrna
found
load
risc
target
mrna
cleav
degrad
success
inhibit
translat
target
gene
sirna
gener
sever
way
case
long
dsrna
introduc
cell
either
viru
endogen
rna
express
ie
microrna
exogen
deliv
dsrna
enzym
dicer
cleav
long
duplex
rna
sirna
anoth
way
introduc
sirna
cell
express
short
hairpin
rna
shrna
plasmid
vector
shrna
transcrib
control
rna
polii
poliii
promot
fold
structur
resembl
sirna
duplex
shrna
process
dicer
sirna
altern
chemic
synthesis
sirna
duplex
mimick
structur
dicerprocess
product
commonli
use
research
gene
silenc
chemic
synthesis
sirna
simpli
bypass
dicer
cleavag
step
gene
silenc
via
sirna
offer
new
paradigm
drug
design
discoveri
compar
tradit
small
molecul
monoclon
antibodi
inhibitor
term
drug
discoveri
convent
smallmolecul
drug
discoveri
involv
iter
screen
random
modif
lead
compound
howev
design
therapeut
sirna
requir
knowledg
target
gene
sequenc
moreov
fact
sirnamedi
rnai
mechan
take
place
cytoplasm
potenti
advantag
generegul
mechan
requir
penetr
nucleu
theoret
rnai
silenc
express
mrna
gene
includ
growth
factor
viral
gene
oncogen
antiapoptot
gene
eg
survivin
gene
deem
nondrugg
small
molecul
inhibitor
consequ
sirnamedi
rnai
use
biolog
tool
assess
gene
function
also
equal
import
sirna
therapeut
potenti
aptam
famili
rnaor
dnabas
oligonucleotid
nt
length
specif
bind
select
target
may
gener
vitro
screen
via
systemat
evolut
ligand
exponenti
enrich
selex
utilis
librari
contain
random
rna
sequenc
varieti
vitro
bind
elut
revers
pcr
amplif
techniqu
allow
select
rna
molecul
effici
bind
specif
receptor
ligand
high
affin
approach
base
fold
abil
rna
complex
structur
reflect
divers
rna
function
natur
adenosin
triphosph
atp
bind
aptam
structur
similar
atpbind
aptam
selex
also
report
prna
bacteri
viru
dna
packag
motor
aptam
select
bind
protein
organ
compound
small
molecul
nucleic
acid
k
nm
rang
aptamerbind
occur
high
specif
format
strong
bind
pocket
analog
antigenantibodi
interact
selex
allow
screen
covari
sever
nucleotid
use
reveal
noncanon
interact
difficult
prove
classic
genet
biochem
approach
therapeut
purpos
aptam
use
bind
inhibit
harm
molecul
serv
target
ligand
nanomed
construct
rna
aptam
transcrib
synthesis
simplifi
need
chemic
conjug
mix
moieti
aptam
use
ligand
specif
deliveri
sirna
prostat
cancer
cell
lymphocyt
microrna
mirna
pathway
anoth
form
rnai
mirna
import
class
short
nonproteincod
rna
origin
endogen
genom
dna
sequenc
mirna
first
transcrib
nucleu
part
long
primari
mirna
transcript
refer
primirna
tail
primirna
hairpin
structur
process
premirna
ribonucleas
drosha
premirna
subsequ
transport
nucleu
cytoplasm
process
matur
mirna
dicer
similar
sirnamedi
silenc
pathway
mirna
load
risc
howev
mode
action
depend
extent
sequenc
complementar
mirna
target
mrna
mirna
match
sequenc
mrna
complet
mirnarisc
complex
mediat
cleavag
mrna
use
mechan
sirna
mirna
partial
match
mrna
sequenc
mirna
risc
complex
induc
translat
inhibit
subsequ
mrna
degrad
endogen
mirna
partial
sequenc
complementar
target
mrna
commonli
target
region
target
mrna
mirna
mechan
fulli
understood
mirna
silenc
arguabl
complex
sirna
silenc
owe
fact
mirna
requir
partial
sequenc
complementar
silenc
gene
addit
hypothesis
singl
mirna
may
silenc
differ
mrna
target
reason
therapeut
use
mirna
key
therapeut
agent
report
diseas
may
link
aberr
mirna
express
function
thu
research
group
target
mirna
therapeut
purpos
use
sirna
antagomir
interfer
aberr
mirna
review
topic
reader
may
refer
soifer
et
al
use
sirna
research
tool
function
genom
vitro
well
establish
rnai
appli
quickli
variou
research
field
numer
report
emerg
use
sirna
power
tool
perform
gene
knockdown
current
aid
commerci
avail
sirna
transfect
reagent
sirnamedi
gene
silenc
becom
common
procedur
studi
gene
function
identifi
diseas
gene
target
addit
research
tool
rnai
hold
great
promis
gene
therapi
silenc
diseasecaus
gene
success
sirna
strategi
gene
therapi
vitro
acceler
effort
vivo
sirna
studi
research
perform
sirna
deliveri
vivo
mice
introduc
nake
sirna
highpressur
tail
inject
highpressur
inject
howev
would
fatal
human
realist
vivo
method
nake
sirna
deliveri
sever
sirna
therapeut
alreadi
clinic
trial
target
superfici
organ
eg
eye
therapeut
agent
directli
inject
organ
sirna
therapeut
studi
current
clinic
trial
includ
agerel
macular
degener
respiratori
infect
chronic
myelogen
leukaemia
cml
type
cancer
howev
strategi
feasibl
deeper
tissu
demand
vector
deliv
system
eg
intraven
inject
human
bodi
well
equip
special
function
destroy
foreign
rna
present
either
bloodstream
tissu
prevent
dsrna
enter
cell
aim
vivo
deliveri
provid
specif
cell
therapeut
concentr
sirna
length
time
requir
inhibit
gene
express
consequ
abil
deliv
therapeut
sirna
specif
ail
cell
stabil
extracellular
intracellular
environ
system
administr
challeng
aspect
advanc
sirna
therapeut
rna
stabil
physiolog
ph
rang
lack
detect
antibodi
respons
adapt
immun
system
biocompat
hint
idea
use
rna
construct
gene
therapi
vitro
transcript
synthesi
purif
sirna
rel
easi
procedur
simpl
gel
electrophoresi
verifi
correct
size
stoichiometri
sirna
howev
nake
sirna
oligom
highli
suscept
nucleas
degrad
order
sirna
surviv
long
enough
maintain
accept
level
tissu
degrad
must
avoid
least
significantli
delay
chemic
modif
sirna
duplex
use
extens
achiev
enhanc
resist
nucleaseinduc
degrad
reduc
offtarget
effect
vivo
applic
chemic
modif
introduc
backbon
sugar
nucleobas
sirna
ideal
modif
enhanc
stabil
sirna
duplex
yet
retain
genesilenc
activ
evalu
chemic
modifi
sirna
perform
cellbas
assay
well
anim
studi
found
gener
sens
strand
nonguid
strand
sirna
toler
modif
antisens
strand
guid
strand
termin
region
sirna
toler
modif
central
region
sever
modif
enhanc
stabil
littl
effect
gene
silenc
even
shown
enhanc
efficaci
significantli
reduc
immunogen
describ
follow
section
phosphorothio
p
backbon
modif
use
modifi
antisens
dna
oligonucleotid
enhanc
stabil
howev
sirna
carri
p
modif
backbon
show
littl
enhanc
nucleas
resist
although
genesilenc
function
retain
sirna
uptak
enhanc
cytotox
observ
p
partial
complet
replac
p
hand
sirna
boranophosphon
p
b
backbon
modif
much
higher
nucleas
resist
nonmodifi
one
addit
genesilenc
activ
sirna
compromis
boranophosphon
modif
introduc
sens
strand
termin
region
duplex
common
modif
sirna
sugar
moieti
lock
nucleic
acid
lna
shown
increas
serum
stabil
sirna
significantli
lna
nucleotid
deriv
link
sugar
och
bridg
addit
also
test
altern
approach
contrast
incorpor
chemic
synthesi
incorpor
vivo
transcript
long
dsrna
pyrimidin
replac
retain
abil
process
recombin
human
dicer
short
sirna
duplex
vivo
studi
duplex
inhibit
target
gene
express
mice
expect
exhibit
prolong
halflif
plasma
compar
nonmodifi
sirna
howev
prolong
halflif
translat
increas
potenc
anim
presum
unfavour
pharmacokinet
featur
modif
entir
sirna
abolish
activ
modif
sens
strand
current
modif
termin
region
sens
strand
commonli
use
commerci
avail
sirna
duplex
addit
substitut
posit
guid
strand
reduc
silenc
offtarget
transcript
contain
complementari
sequenc
seed
region
guid
strand
mook
et
al
tri
endmodifi
heavili
modifi
sirna
strand
lna
endmodifi
heavili
modifi
rna
enhanc
serum
stabil
h
respect
silenc
abil
howev
decreas
heavili
modifi
strand
suggest
rnai
mechan
toler
radic
lna
modif
sirna
chemic
structur
one
might
assum
sirna
must
protect
nucleas
serum
cytoplasm
cytoplasm
stabil
unclear
chiu
et
al
show
modifi
nucleotid
last
longer
cytoplasm
literatur
report
sirna
internalis
modifi
nonmodifi
sirna
similar
stabil
nucleobas
modif
sirna
includ
residu
residu
residu
residu
residu
uridin
residu
inosin
residu
residu
parrish
colleagu
found
sirna
remain
activ
inclus
uridin
abolish
activ
c
elegan
nucleobas
modif
toler
sens
standtermin
region
antisens
strandcentr
region
sirna
duplex
recent
studi
demonstr
dna
nucleotid
use
seed
region
sirna
nt
guid
strand
still
retain
silenc
abil
end
modif
sirna
allow
conjug
ligand
folat
cholesterol
biotin
fluoresc
molecul
offer
opportun
enhanc
pharmacolog
characterist
introduc
special
featur
sirna
differ
studi
report
modif
sens
strand
well
toler
retain
sirna
function
conjug
cholesterol
folat
group
sens
strand
confer
sirna
druglik
properti
enabl
liver
jejunum
cancer
cellselect
deliveri
antisens
strand
found
group
essenti
rnai
activ
sirna
duplex
group
either
introduc
chemic
synthesi
phosphoryl
endogen
kinas
block
terminu
function
antisens
strand
abolish
genesilenc
activ
sirna
howev
modif
still
toler
long
present
effect
modif
antisens
strand
less
conclus
exampl
well
toler
led
loss
silenc
function
chemic
synthesis
sirna
duplex
often
contain
two
deoxynucleotid
overhang
resembl
sirna
duplex
produc
dicer
inclus
increas
stabil
sirna
duplex
facilit
load
duplex
risc
complex
subsequ
gene
silenc
addit
presenc
may
help
reduc
immun
respons
shown
recent
studi
sirna
duplex
variou
length
activ
interferon
system
absenc
overhang
report
potent
induct
interferon
alpha
beta
short
singlestrand
rna
ssrna
transcrib
rna
polymeras
initi
triphosph
trigger
interferon
respons
despit
display
signific
serum
resist
improv
stabil
chemic
modif
system
deliv
sirna
solv
anoth
challeng
issu
deliv
sirna
vivo
sirna
size
averag
size
singl
sirna
molecul
well
nm
addit
polyanion
natur
rna
make
difficult
penetr
cell
membran
nonformul
sirna
report
easili
excret
bodi
therefor
molecul
even
stabilis
subject
renal
filtrat
administ
bloodstream
sirna
would
suffer
poor
pharmacokinet
limit
extent
durat
effect
increas
size
sirna
transcrib
longer
piec
chemic
link
ie
disulfid
bond
streptavadinbiotin
etc
nucleic
acid
protein
surfac
form
larger
particl
anoth
approach
achiev
increas
particl
size
enhanc
stabil
extracellular
intracellular
environ
involv
extranucleotid
materi
polym
liposom
togeth
sirna
form
nanoparticl
increas
size
protect
sirna
nucleas
degrad
nanoparticl
form
conjug
biolog
inert
polym
directli
sirna
prepar
liposom
envelop
sirna
molecul
type
nanoparticl
proven
success
stabilis
sirna
serum
nanoparticl
deliveri
sirna
also
potenti
improv
pharmacokinet
pharmacodynam
biodistribut
toxicolog
newli
emerg
therapeut
modal
commonli
accept
size
nanoparticl
paramount
effect
deliveri
diseas
tissu
mani
author
suggest
particl
rang
nm
larg
nm
optim
size
nonvir
vector
larg
enough
retain
bodi
yet
small
enough
access
cell
surfac
receptor
pass
cell
membran
receptormedi
endocytosi
howev
nanoparticl
diamet
greater
nm
recognis
reticuloendotheli
system
re
re
made
mononuclear
phagocyt
origin
bone
marrow
matur
bloodstream
monocyt
matur
begin
localis
outsid
bloodstream
near
number
tissu
includ
lymph
node
liver
lung
digest
track
spleen
transform
fulli
matur
macrophag
macrophag
recognis
internalis
degrad
larg
particl
process
call
opsonis
opsonis
process
opsonin
origin
matur
macrophag
coat
foreign
substanc
like
bacteria
nanoparticl
coat
drive
bind
ingest
foreign
substanc
macrophag
process
larg
respons
short
halflif
nanoparticl
larger
nm
must
taken
account
design
nanoparticl
sirna
deliveri
avoid
recognit
re
nanoparticl
diamet
less
approxim
nm
subject
renal
filtrat
kidney
larg
respons
whole
bodi
homeostasi
effici
remov
wast
matter
bodi
howev
size
limit
globular
filtrat
preclud
larg
molecul
subject
process
specif
challeng
associ
use
nanoparticl
system
drug
deliveri
vehicl
continu
stabilis
particl
increas
circul
time
target
deliveri
produc
rna
nanoparticl
appropri
size
nm
chimer
rna
complex
construct
fuse
sirna
prna
bacteriophag
motor
prna
increas
size
achiev
make
motor
prna
dimer
trimer
format
increas
rna
particl
size
nm
extend
halflif
therapeut
rna
complex
vivo
avoid
short
retent
time
rna
molecul
avoid
problem
low
deliveri
due
larger
size
describ
anoth
challeng
deliv
therapeut
sirna
vivo
origin
nonspecif
distribut
sirna
throughout
bodi
administ
system
system
deliveri
decreas
local
therapeut
concentr
ail
cell
addit
sirna
surmount
blood
vessel
endotheli
wall
multipl
tissu
barrier
abl
reach
target
cell
exert
therapeut
effect
diseas
cell
intact
doublestrand
sirna
need
effici
transfer
cell
sirna
effici
enter
cell
without
assist
one
approach
enhanc
sirna
cellular
uptak
complex
sirna
molecul
within
lipid
formul
similar
wide
use
transfect
reagent
addit
enhanc
optimis
pharmacokinet
sirna
nanoparticl
deliveri
offer
addit
advantag
abl
promot
desir
tissu
distribut
profil
although
like
target
strategi
play
role
tissu
select
clear
target
mechan
employ
given
nanoparticl
singularli
direct
biodistribut
depend
diseas
patholog
properti
deliveri
system
passiv
target
diseas
site
occur
nanoparticl
size
surfac
charg
play
key
role
halflif
nanoparticl
also
govern
tissu
accumul
rel
high
concentr
nanoparticl
one
drive
forc
behind
theori
barrier
protect
tissu
vari
poros
pore
size
number
particular
tumour
tissu
surround
rapidli
grow
andor
disorganis
vasculatur
support
effici
lymphat
drainag
nanoparticl
abl
extravas
accumul
leaki
vasculatur
tumour
phenomenon
call
enhanc
permeabl
retent
epr
effect
therefor
sirna
nanoparticl
may
passiv
target
tissu
stay
within
size
rang
optim
epr
epr
method
effici
enhanc
uptak
highli
nonspecif
may
suffici
direct
tissu
distribut
sirna
better
direct
tissu
distribut
simultan
enhanc
uptak
number
target
moieti
explor
small
molecul
singlechain
monoclon
antibodi
receptorbind
aptam
use
enhanc
uptak
case
direct
tissu
distribut
see
section
titl
ligandtarget
sirna
deliveri
specif
cellular
uptak
occur
via
receptormedi
endocytosi
case
nanocarri
functionalis
target
ligand
internalis
upon
bind
ligandmodifi
nanocarri
cellsurfac
receptor
transport
diseas
site
endosom
vesicl
cancer
develop
gradual
complic
process
often
accompani
accumul
genet
altern
lead
unregul
cancerpromot
oncogen
disabl
tumour
suppressor
gene
oftentim
genet
abnorm
dictat
malign
behaviour
tumour
allow
unrestrict
cell
prolifer
invas
adjac
tissu
metastasi
primari
tumour
site
format
new
blood
vessel
resist
chemotherapeut
drug
cancer
gene
therapi
aim
correct
genet
abnorm
suppress
patholog
gene
reexpress
function
tumour
suppressor
gene
potenti
sirna
cancer
therapi
recognis
earli
hypothet
regul
express
cancer
cell
leav
normal
gene
unperturb
addit
genesilenc
effici
equival
dose
sirna
proven
higher
antisens
oligonucleotid
ribozym
strategi
initi
popular
abil
suppress
gene
express
purpos
cancer
gene
therapi
one
import
factor
success
rnaibas
cancer
therapi
choos
right
target
gene
great
effort
made
identifi
molecular
target
cancer
therapi
common
target
fall
categori
given
follow
guardian
genom
inactiv
point
mutat
human
cancer
sirna
use
suppress
express
mutat
restor
function
wildtyp
gene
program
cell
death
apoptosi
commonli
deregul
cancer
especi
drugresist
tumour
sirnabas
therapeut
induc
apoptosi
cancer
cell
target
antiapoptot
factor
survivin
suppress
antiapoptot
gene
sirna
found
induc
apoptosi
variou
cancer
sensitis
chemotherapi
drug
specif
survivin
attract
consider
amount
interest
sinc
survivin
present
foetal
tissu
cancer
absent
normal
adult
tissu
thu
silenc
survivin
could
tumourspecif
therapi
without
damag
normal
tissu
increas
knowledg
neoplast
cellsignal
pathway
result
sever
novel
drug
cancer
therapi
includ
inhibitor
protein
tyrosin
kinas
bcrabl
monoclon
antibodi
receptor
inhibit
critic
signal
transduc
involv
prolifer
surviv
pathway
especi
protein
kinas
consid
promis
direct
develop
sirnabas
cancer
therapeut
studi
conduct
wohlbold
et
al
indic
rnai
select
inhibit
bcrabldepend
cell
growth
cml
addit
sirna
bcrabl
significantli
increas
sensit
cml
cell
treatment
anticml
drug
sever
proofofconcept
studi
use
sirna
silenc
express
perform
mous
model
pancreat
ovarian
cancer
vascular
endotheli
growth
factor
vegf
play
critic
role
patholog
angiogenesi
develop
cancer
vegf
sirna
almost
complet
inhibit
secret
growth
factor
human
prostat
cancer
cell
line
dramat
suppress
tumour
angiogenesi
tumour
growth
xenograft
model
mice
pglycoprotein
multipl
drug
resist
mdr
one
major
caus
unsuccess
chemotherapi
cancer
patient
sirna
pglycoprotein
gene
result
reduct
express
two
gene
vitro
mice
inhibit
pglycoprotein
cell
retroviralmedi
short
hairpin
shrna
confer
increas
sensit
cell
cytotox
drug
includ
vincristin
paclitaxel
doxorubicin
sirna
offer
opportun
treat
viral
infect
suppress
viral
transcript
host
cell
virus
differ
famili
inhibit
sirna
high
effici
includ
rna
reversetranscrib
dna
virus
mani
virus
pose
major
threat
human
health
human
immunodefici
viru
hiv
hepat
b
viru
hbv
sever
acut
respiratori
syndrom
coronaviru
polio
viru
influenza
viru
herp
simplex
viru
suggest
rnai
appli
inhibit
replic
everi
class
viru
sinc
transcript
mrna
critic
step
need
replic
virus
viral
host
gene
essenti
viral
replic
use
target
sirnabas
viral
therapi
suppress
replic
silenc
viral
gene
involv
earli
event
viral
life
cycl
bind
cellular
receptor
entri
transcript
translat
earli
gene
consid
effect
silenc
late
gene
initi
studi
perform
p
sharp
group
use
sirna
inhibit
hiv
replic
vitro
heladeriv
cell
line
express
coreceptor
hiv
sirna
viral
gene
gag
result
inhibit
viral
product
follow
hiv
infect
sinc
mutant
strain
hiv
emerg
constantli
highli
conserv
sequenc
essenti
gene
gag
pol
int
vpu
often
chosen
target
howev
target
highli
conserv
sequenc
may
translat
directli
effect
genesilenc
suppress
gene
express
effect
panel
sirna
test
anoth
studi
influenza
viru
sirna
design
sever
conserv
region
viral
genom
includ
np
pa
ns
gene
two
sirna
nucleocapsid
rna
transcriptas
much
effect
other
therefor
actual
inhibit
effici
ration
design
sirna
still
need
verifi
experi
anoth
strategi
deal
potenti
viral
genom
mutat
use
cocktail
sirna
combin
sirna
target
one
sever
essenti
gene
viru
cocktail
differ
sirna
target
mrna
target
also
use
combat
viral
gene
undergo
frequent
mutat
downsid
cocktail
approach
potenti
difficulti
pinpoint
sirna
induc
interferon
respons
offtarget
effect
target
host
gene
rnai
also
effect
prevent
treatment
viru
infect
knock
express
sirna
effect
inhibit
entri
replic
hiv
howev
silenc
host
receptor
critic
biolog
function
may
result
unaccept
side
effect
target
deliveri
sirna
viralinfect
cell
becom
essenti
supplement
approach
exampl
sirna
conjug
antibodi
deliv
specif
mous
melanoma
cell
line
stabli
express
hiv
mimic
antigen
present
hivinfect
cell
transcript
chemic
synthesi
fusion
mutagenesi
conjug
basic
techniqu
rna
technolog
selfassembl
nanoparticl
rna
rnachem
conjug
promin
bottomup
approach
obtain
nanometres
nanostructur
complex
varieti
nanotechnolog
nanomedicin
applic
combin
chemic
biolog
techniqu
success
integr
nanotechnolog
approach
rna
nanotechnolog
reli
upon
cooper
interact
intraor
interrna
molecul
spontan
fold
assembl
form
larger
twoor
threedimension
complex
appropri
structur
stoichiometri
within
realm
selfassembl
fold
two
main
subcategori
nontempl
assembl
templatedirect
assembl
nontempl
assembl
method
sought
ensur
conjug
modif
affect
fold
function
rna
molecul
nontempl
assembl
involv
format
larger
structur
individu
compon
without
influenc
extern
forc
includ
nontempl
categori
ligat
chemic
conjug
coval
linkag
looploop
interact
rna
format
macromolecul
structur
interact
format
multim
use
bacteriophag
prna
build
block
construct
micrometres
rna
array
potenti
tissu
wound
repair
report
templatedirect
assembl
involv
interact
rna
molecul
one
anoth
influenc
specif
extern
structur
forc
spatial
constraint
rna
transcript
hybridis
replic
anneal
dnarna
mold
replica
product
part
categori
deliveri
novel
therapeut
use
nanoparticl
one
promis
embodi
nanotechnolog
without
improv
sirna
realis
full
potenti
ideal
system
deliveri
vector
nm
size
nontox
nonimmunogen
stabl
capabl
effici
intracellular
deliveri
possess
specif
target
abil
one
key
reason
antibodi
therapi
current
mani
problem
clinic
scientist
look
new
solut
nanotechnolog
order
ration
engin
effect
vector
key
biolog
featur
mechan
identifi
appropri
avoid
exploit
design
biolog
aspect
includ
choic
materi
toxic
system
immun
cellular
respons
dynam
ph
oxid
environ
rnaprotein
rnarna
interact
coval
versu
noncoval
bond
passiv
versu
activ
internalis
mechan
combin
poli
ethylen
glycol
fusogen
nonfusogen
lipid
dendrim
liposom
polyc
nucleic
acid
modif
prna
fuse
system
target
moieti
use
improv
pharmacolog
rnabas
therapeut
addit
although
feasibl
therapeut
approach
yet
investig
nanotub
also
use
carrier
sirna
follow
section
highlight
current
effort
use
nanoparticl
technolog
enabl
system
deliveri
sirna
therapeut
purpos
sever
nucleic
acidbas
sirna
vector
report
rational
use
nucleic
acidbas
vector
stem
fact
construct
vector
may
simpler
compar
lipoplex
polyplex
strategi
without
complex
protein
nucleic
acid
report
elicit
antibodi
respons
nucleic
acid
within
nanometr
regim
construct
larger
structur
via
bottomup
assembl
control
manner
molecul
conjug
directli
end
nucleic
acid
strand
add
addit
function
report
shown
design
correctli
nucleic
acidbas
construct
prna
sirna
chimera
still
abl
process
dicer
function
sirna
reiter
two
criteria
success
nonvir
sirna
vector
nucleic
acidbas
vector
must
adequ
size
rnabas
vector
stabl
rnase
nucleas
undoubtedli
nucleic
acidbas
vector
use
must
incorpor
rnaseresist
nucleotid
analogu
success
vivo
mcnamara
et
al
construct
rnabas
sirna
vector
vitro
transcript
construct
featur
sirna
domain
well
rna
aptam
target
prostat
cancer
cell
zhang
et
al
construct
hybrid
dna
rna
molecul
use
tether
approach
sens
strand
sirna
contain
nt
overhang
tether
singlestrand
folatedna
strand
complementari
nt
sequenc
synthesis
separ
anneal
overhang
rational
folat
moieti
would
facilit
target
deliveri
folatereceptor
posit
tumour
cell
internalis
rnaseh
degrad
dna
rna
hybrid
strand
would
degrad
hybrid
portion
vector
liber
sirna
strand
particip
silenc
although
author
show
data
vector
process
hypothesis
author
report
rel
mrna
knockdown
huvec
folatetarget
sequencespecif
manner
construct
elicit
signific
interferon
respons
liposom
wide
use
deliv
cargo
target
cell
major
class
nonvir
deliveri
vector
liposom
among
first
studi
develop
therefor
characteris
neutral
lipid
exhibit
low
toxic
low
immunogen
easi
product
liposom
also
attract
choic
gene
deliveri
formul
nm
size
byproduct
biocompat
lipid
encapsul
payload
ie
sirna
simpli
involv
mix
incub
specif
deliveri
achiev
conjug
ligand
lipid
molecul
proceed
form
liposom
common
neutral
charg
lipid
includ
dopc
dope
neutral
charg
dopc
encapsul
sirna
solut
simpl
mix
vivo
studi
reveal
reduct
xenograph
tumour
volum
compar
treatment
group
also
demonstr
dopc
could
deliv
sirna
focal
adhes
kinas
kill
ovarian
cancer
cell
implant
mice
instead
use
neutral
lipid
molecul
cation
lipid
ad
neutral
lipid
formul
cation
charg
electrostat
complex
sirna
achiev
robust
construct
neutral
lipid
facilit
fusion
host
cell
membran
cation
liposom
complex
nucleic
acid
term
lipoplex
amino
hexanoyl
propan
dotap
cation
liposom
conjug
poli
arginin
improv
cell
entri
protect
sirna
serum
degrad
lipoplex
analogu
phospholipid
found
cardiac
muscl
tissu
call
cardiolipin
success
deliv
sirna
exhibit
less
toxic
increas
deliveri
effici
compar
dotap
cation
liposom
also
report
deliv
sirna
tumour
necrosi
factor
tnf
alpha
experiment
model
rheumatoid
arthriti
previou
two
case
enhanc
distribut
liposom
target
site
believ
mediat
epr
effect
inflammatori
tissu
solid
tumour
vasculatur
endotheli
cell
junction
becom
leaki
chang
lab
use
immunolipoplex
dotap
dope
mixtur
attach
target
ligand
ie
monoclon
antibodi
transferrin
receptor
although
rel
larg
nm
diamet
immunolipoplex
conjug
repeat
unit
phsensit
histidinelysin
hk
peptid
buffer
acid
endosom
releas
sirna
payload
increas
silenc
potenc
compar
lipoplex
without
hk
peptid
vivo
author
found
immunolipoplex
hk
sirna
treatment
conjunct
tradit
drug
best
effect
vivo
compar
immunoplex
sirna
sirna
treatment
alon
although
lack
target
moieti
develop
stabl
nucleicacidlipid
particl
snalp
repres
excit
recent
direct
lipidbas
system
rnai
particl
mixtur
neutral
lipid
cation
lipid
poli
ethylen
glycol
peg
addit
layer
peg
improv
retent
time
much
h
studi
hbv
replic
mous
model
prolong
halflif
snalpsirna
serum
observ
three
daili
intraven
inject
therapeut
viabl
dose
mg
kg
snalpsirna
reduc
hbv
level
significantli
reduct
hbv
last
week
anoth
studi
show
snalpsirna
rapidli
silenc
apob
gene
liver
cynomolgu
monkey
dose
mg
kg
result
reduct
serum
cholesterol
addit
silenc
effect
found
last
day
rna
treatment
size
snalp
like
play
signific
role
limit
biodistribut
morrissey
et
al
show
snalp
gener
accumul
liver
spleen
deliv
signific
amount
rna
tissu
snalpsirna
deliveri
gener
well
toler
evalu
toxic
reveal
transient
increas
liver
enzym
activ
lipoplex
deliveri
sirna
success
sever
report
mechan
releas
payload
lipoplex
suggest
continu
research
mechan
releas
may
lead
develop
biorespons
vector
achiev
higher
silenc
given
dose
polym
anoth
class
materi
use
deliv
nucleic
acid
sirna
come
varieti
molecular
weight
function
group
peg
uncharg
polym
high
biocompat
use
mani
biomed
applic
often
use
block
element
ie
block
copolym
coat
pegyl
polym
biomateri
prevent
nonspecif
bind
protein
peg
also
use
materi
basi
sirna
vector
conjug
polym
sirna
encapsul
pegpolymersirnapeg
pattern
use
produc
nanos
block
ionom
spheric
polyion
complex
pic
micel
exploit
natur
cytoplasm
endocyt
environ
peg
link
sirna
via
phsensit
bond
design
rational
upon
internalis
endosom
reduct
acid
environ
break
bond
releas
sirna
particip
silenc
contrast
uncharg
polym
cation
polym
electrostat
complex
polyanion
backbon
nucleic
acid
achiev
robust
noncoval
interact
varieti
synthet
biolog
polyc
polycationcontain
block
copolym
also
use
deliv
sirna
exampl
materi
review
next
polyethyleneimin
pei
synthet
polym
highli
branch
network
high
cation
charg
densiti
due
abil
condens
nucleic
acid
mediat
endocytosi
pei
variou
molecular
weight
degre
branch
use
deliv
nucleic
acid
vitro
vivo
lowmolecularweight
pei
shown
effect
condens
rna
protect
nucleas
cellfre
rnase
digest
assay
use
serum
addit
benefit
pei
exhibit
proton
spong
effect
water
swell
endosom
amin
group
polym
buffer
lower
ph
endosom
subsequ
ruptur
endosom
membran
allow
sirna
escap
complex
cytoplasm
urbanklein
et
al
found
peicomplex
sirna
show
protect
degrad
h
vivo
wherea
uncomplex
sirna
complet
degrad
within
min
anoth
studi
peisirna
complex
deliv
intraven
administr
prevent
treat
influenza
viru
replic
mice
found
peisirna
distribut
multipl
organ
deliv
lung
preferenti
intraven
iv
inject
howev
whether
lung
prefer
due
trap
polymersirna
complex
lung
macrophag
remain
investig
trap
bronch
nanoparticl
lung
macrophag
liver
kuffer
cell
one
current
challeng
sirna
deliveri
studi
howev
show
pei
exhibit
high
toxic
vitro
therefor
rais
concern
vivo
use
attempt
decreas
potenti
toxic
pei
combin
peipeg
abl
stabilis
complex
sirna
nanos
particl
also
prevent
nonspecif
bind
cell
protein
pegyl
reduc
pei
toxic
particl
size
increas
dramat
upon
pegyl
cyclodextrinbas
polyc
cdp
deliv
therapeut
molecul
rang
small
molecul
drug
plasmid
recent
sirna
cdp
nm
diamat
compos
cation
polym
funnelshap
cyclodextrin
molecul
integr
polym
strand
cation
polym
complex
sirna
cyclodextrin
serv
adapt
molecul
differ
functionalis
adamantan
molecul
plug
cdp
functionalis
adamantan
molecul
give
cdp
addit
function
individu
compon
cdp
known
rel
nontox
design
specif
highli
nontox
nonvir
vector
vivo
studi
includ
cdp
deliv
nonhuman
primat
cdp
contain
sirna
cancer
fusion
gene
product
studi
shortand
longterm
administr
cdpsirna
decreas
implant
tumour
volum
author
claim
cdp
protect
rna
serum
modifi
nucleotid
requir
applic
cdp
functionalis
functionalis
adamantanetransferrin
adamantanepeg
conjug
result
pegyl
transferrintarget
cdp
deliv
sirna
anim
dosag
like
amen
therapeut
use
human
perhap
astonish
characterist
approach
result
sirna
complex
even
sirna
contain
immun
stimulatori
sequenc
includ
produc
immun
stimul
like
seen
sirnalipid
complex
gener
sirna
must
use
abrog
respons
chitosan
cation
polysaccharid
polym
found
natur
well
characteris
studi
biomed
applic
rang
nucleic
acid
deliveri
bandag
major
draw
chitosan
biocompat
optim
cation
charg
chitosanbas
nanoparticl
control
ratio
amin
phosphat
n
p
determin
optim
n
p
ratio
complex
much
sirna
possibl
howard
et
al
use
chitosansirna
nanoparticl
mice
specif
knock
gfp
express
lung
addit
sirna
dramat
affect
size
particl
particl
even
without
sirna
nm
recent
studi
shown
iv
deliveri
sirna
antirhoa
load
chitosanco
polyisohexylcyanoacryl
nanoparticl
effici
inhibit
growth
aggress
xenograft
breast
cancer
mice
dendrim
highli
branch
polym
molecul
proven
use
mask
charg
sirna
long
enough
vivo
deliveri
approach
polycation
dendrim
conjug
target
lipid
moieti
complex
sirna
result
interf
nanoparticl
inop
use
deliv
modifi
sirna
liver
knock
express
apolipoprotein
b
apob
lower
serum
cholesterol
inhibit
apob
occur
concentr
low
mg
kg
mice
fall
within
rang
gener
agre
amen
effect
dose
human
dynam
polyconjug
roughli
nm
size
much
smaller
snalp
inopsirna
complex
also
report
deliv
sirna
vitro
vivo
recent
studi
demonstr
abil
target
hepatocyt
via
nacetylgalactosamin
nag
driven
target
mechan
dynam
polyconjug
engin
function
group
vector
stabl
ph
degrad
acid
environ
endosom
internalis
endosom
endosom
disrupt
via
endosomolyt
agent
sirna
releas
cytoplasm
could
prove
advantag
develop
sirna
complex
uniqu
biodistribut
profil
one
drawback
approach
chemistri
necessari
synthesis
dynam
polyconjug
involv
vector
prepar
protein
use
nanos
platform
deliv
sirna
posit
charg
protein
like
protamin
use
noncoval
bind
sirna
mask
neg
charg
intend
target
reach
approach
use
prohibit
hiv
infect
vitro
slow
tumour
growth
vivo
recent
use
protamineantibodi
fusion
protein
select
target
activ
leucocyt
report
demonstr
propos
possibl
interf
select
undesir
pathogen
immun
stimul
without
induc
global
immunosuppress
respons
minakuchi
et
al
employ
atelocollagen
purifi
pepsintr
form
type
collagen
cow
deliv
sirna
protein
complex
sirna
simpl
mix
phosphat
buffer
atelocollagensirna
treatment
method
use
localis
inject
method
xenograph
tumour
vivo
studi
use
atelocollagensirna
show
faster
transfect
enhanc
silenc
luciferaseexpress
xenograft
tumour
compar
liposom
atellocollagenmedi
sirna
deliveri
also
use
kinouchi
et
al
demonstr
effici
sirna
target
myostatin
neg
regul
skelet
muscl
growth
stabl
metal
core
nanoparticl
differ
coat
layer
serv
foundat
build
larger
nanoparticl
core
construct
iron
oxid
iron
cobalt
iron
gold
iron
nickel
coat
materi
includ
polym
sugar
compound
gener
coreshel
structur
sirna
conjug
metal
core
nanoparticl
via
thiol
dextran
biotinstreptavadin
linkag
metal
coat
cation
polym
addit
depend
type
core
materi
particl
track
via
magnet
reson
imag
system
inject
evalu
target
manipul
target
tissu
use
extern
magnet
superparamagnet
iron
oxid
coat
pei
complex
nucleic
acid
particl
complex
sirna
gfp
nearli
complet
silenc
gene
express
vitro
anoth
group
use
superparamagnet
crosslink
iron
oxid
coat
dextran
conjug
polyarginin
facilit
cell
entri
sirna
gfp
silenc
gfp
express
mice
metal
nanoparticl
approach
deserv
continu
attent
major
hurdl
vivo
deliveri
toxic
demonstr
advantag
method
target
diseas
cell
organ
tissu
increas
silenc
potenc
given
dose
sirna
nanoparticl
specif
celltarget
also
prevent
side
effect
avoid
nondiseas
cell
differ
stage
diseas
abnorm
cell
neoplast
viralinfect
cell
express
varieti
uniqu
marker
specif
antigen
receptor
surfac
signatur
molecul
provid
valuabl
recognit
site
develop
target
deliveri
sirna
antibodi
aptam
small
peptid
ligand
bind
signatur
molecul
high
specif
affin
studi
extens
abil
guid
sirna
target
tissu
cell
attach
target
moieti
sirna
vector
mention
briefli
construct
discuss
section
titl
nonvir
carrier
sirna
deliveri
categoris
elabor
variou
target
strategi
ad
benefit
stabil
enabl
variou
possibl
direct
conjug
sirna
may
serv
simpl
yet
effect
way
target
select
diseas
cell
tissu
asialoglycoprotein
receptor
asgpr
bind
varieti
carbohydr
predominantli
highli
express
liver
cell
asgpr
vivo
target
kim
et
al
deliv
sirnaencod
dna
plasmid
via
pei
vector
galactos
conjug
pei
peg
gpp
via
peptid
bond
min
system
deliv
gpp
gamma
imag
mice
reveal
high
target
deliveri
gpp
liver
tumour
compar
heart
kidney
bladder
oishi
et
al
also
target
asgpr
acidcleav
lactosyl
peg
sirna
block
polyion
complex
show
competit
target
knockdown
vitro
carbohydratenag
success
use
target
hepatocyt
studi
use
dynam
polyconjug
deliv
sirna
folat
receptor
fr
overexpress
cell
surfac
sever
type
cancer
diseas
cell
express
minim
quantiti
normal
cell
except
kidney
although
use
vitro
molecular
folat
conjug
cation
polym
pei
pll
promisingli
achiev
high
target
sirna
deliveri
target
gene
silenc
nasopharyng
carcinoma
cell
incorpor
folateamp
vitro
rna
transcript
system
singl
folat
molecul
place
rna
molecul
use
dimertrim
format
mechan
complex
contain
sirna
folat
gener
specif
deliv
varieti
cancer
cell
express
folat
receptor
cholesterol
cholesterol
analogu
serv
target
ligand
cholesterol
endocytos
cholesterol
receptor
hepatocyt
sirna
conjug
intrasystem
deliv
mice
knock
apolipoprotein
b
apob
overexpress
lipoprotein
involv
coronari
arteri
diseas
cholesterol
moieti
confer
sirna
druglik
properti
good
stabil
cellular
deliveri
tissu
bioavail
nake
sirna
apob
show
localis
particular
tissu
wherea
sirnacholesterol
molecul
deliv
consider
concentr
hepatocyt
follow
small
level
heart
kidney
depend
region
apob
mrna
target
sirnacholesterol
exhibit
reduct
apob
vivo
mani
peptid
protein
transferrin
antibodi
use
tradit
purpos
celltarget
gene
deliveri
specif
target
recognit
excel
howev
larg
size
protein
induct
antibodi
part
disadvantag
use
protein
gene
deliveri
nanotechnolog
peptid
ligand
obviou
choic
target
moieti
nanoparticl
due
known
specif
one
wellcharacteris
target
strategi
exploit
phenomenon
tumour
must
produc
blood
vessel
provid
nutrient
fastgrow
tumour
cell
process
known
angiogenesi
rgd
peptid
repres
anoth
type
target
peptid
mediat
tumourspecif
deliveri
bind
transmembran
integrin
overexpress
mani
type
cancer
mediat
entri
cargo
cell
rgd
sequenc
coupl
surfac
sever
sirna
vector
aim
target
kill
tumour
cell
leav
normal
cell
rel
unharm
rgd
conjug
peipeg
polym
fluoresc
microscopi
reveal
fitcsirna
complex
rgdpeipeg
localis
tumour
cell
tissu
cancer
cell
upregul
certain
cell
surfac
receptor
correspond
larger
protein
ligand
transferrin
transferrin
conjug
peg
molecul
incub
nonconjug
peg
cdp
three
compon
selfassembl
nanos
particl
cdp
region
form
core
peg
pegtransferrin
molecul
form
surfac
addit
transferrintarget
moieti
improv
deliveri
luciferas
plasmid
significantli
lab
also
use
transferrincdp
deliv
sirna
metastasis
tumour
express
luciferas
bioluminesc
imag
show
nontarget
cdp
significantli
decreas
size
metastasis
tumour
transferrintarget
cdp
show
reduct
metastasis
tumour
growth
compar
control
recent
studi
cynomolgu
monkey
show
multipl
system
dose
transferrinconjug
cdp
contain
sirna
safe
administ
nonhuman
primat
antibodi
fuse
variou
drug
deliveri
platform
target
agent
monoclon
antibodi
oncogen
vegf
well
develop
wide
use
cancer
treatment
clinic
attempt
creat
trival
particl
recent
studi
tan
et
al
conjug
antibodi
chitosansirnaquantum
dot
nanoparticl
result
show
trival
particl
significantli
silenc
gfp
instead
use
transferrin
molecul
directli
pirollo
et
al
conjug
singlechain
monoclon
antibodi
fragment
scfv
target
transferrin
receptor
nanoimmunolipoplex
contain
fluoresc
sirna
target
nanoimmunolipoplex
show
dramat
increas
target
primari
metastat
tumour
compar
untarget
sirna
treatment
addit
wherea
system
deliv
nanoparticl
commonli
accumul
liver
studi
show
consider
amount
sirna
detect
liver
studi
perform
lieberman
group
heavi
chain
fab
fragment
antibodi
envelop
protein
fuse
nucleic
acidcondens
protein
protamin
abprotamin
serv
deliveri
vehicl
antibodi
protamin
sirna
construct
target
hiv
gag
gene
effect
suppress
target
gene
express
inhibit
hiv
replic
hardtotransfect
primari
cell
infect
hiv
addit
intraven
inject
antibodi
protamin
sirna
complex
mous
model
led
substanti
suppress
growth
hiv
envelopeexpress
melanoma
studi
fusion
protein
contain
singlechain
antibodi
receptor
also
abl
deliv
sirna
specif
breast
cancer
cell
studi
repres
major
landmark
success
design
vivo
deliveri
antibodytarget
therapeut
sirna
particl
follow
approach
anoth
studi
construct
antibodytarget
cation
liposom
deliv
sirna
cyclin
treat
inflammatori
bowel
diseas
one
drawback
peptidebas
target
moieti
induct
antibodi
respons
would
abolish
longterm
dose
schedul
unless
humanis
antibodi
utilis
aptam
also
explor
target
agent
deliv
sirna
current
major
challeng
ligandbas
deliveri
short
use
specif
cell
receptor
target
addit
mani
cell
receptor
simpli
internalis
cargo
ligand
interact
receptor
receptorbind
rna
aptam
may
prove
success
area
mention
section
aptam
bind
small
molecul
ie
metabolit
protein
cell
surfac
receptor
etc
high
affin
specif
compar
antigenantibodi
interact
applic
aptam
sirna
vector
includ
use
aptam
target
lymphocyt
psma
aptam
target
prostat
cancer
membran
antigen
signatur
surfac
molecul
prostat
cancer
guo
guo
p
unpublish
result
work
mcnamara
et
al
rna
aptam
link
sirna
form
rna
chimera
vitro
transcript
anneal
system
administr
construct
specif
inhibit
tumour
growth
xenograft
model
prostat
cancer
mice
contrast
system
use
guo
mcnamara
approach
howev
allow
incorpor
imag
nucleotid
construct
shown
psmasirna
internalis
psmaposit
cell
treatment
reduc
xenograph
tumour
volum
similar
studi
prostat
cancerspecif
deliveri
sirna
observ
coupl
psma
aptam
via
streptavidin
bridg
proteinfre
platform
use
rna
aptam
target
ligand
attract
rna
recognis
antibodi
thu
suggest
improv
longterm
dose
regimen
rna
dna
aptam
develop
clinic
relev
target
specif
cancer
diseas
marker
aptam
deliveri
approach
becom
power
rnabas
sirna
vector
inspir
molecular
machineri
within
bacteriophag
dna
packag
motor
motor
compris
varieti
packag
protein
dna
six
rna
molecul
nt
length
form
hexamer
ring
hand
hand
interact
extens
structur
function
studi
motor
reveal
rna
hexam
play
essenti
role
genom
dna
transloc
packag
thu
term
packag
rna
prna
sinc
recent
prna
monom
design
carri
varieti
therapeut
agent
includ
sirna
hammerhead
ribozym
target
ligand
folat
receptorbind
rna
aptam
prna
monom
differ
cargo
molecul
subsequ
use
assembl
dimer
trimer
hexam
molecul
enabl
use
nanocarri
polyval
deliveri
vehicl
dimer
trimer
hexamer
prna
structur
easili
form
via
interact
ration
design
prna
monom
interlock
left
right
loop
nucleotid
sequenc
defin
region
individu
prna
monom
easili
manipul
accommod
specif
rna
sequenc
without
alter
prna
fold
structur
abil
form
multim
via
interlock
loop
commonli
accept
rna
induc
lower
antibodi
respons
compar
protein
henc
use
rna
deliveri
vehicl
potenti
reduc
immun
respons
reject
protein
vector
repeat
longterm
drug
administr
chronic
diseas
prnaderiv
nanoparticl
small
size
nm
narrow
size
distribut
put
optim
size
rang
cell
uptak
nm
make
particularli
suit
vivo
system
deliveri
abil
easili
functionalis
prna
multim
targetspecif
localis
feasibl
multipl
therapeut
agent
deliveri
use
singl
vehicl
signific
advantag
prna
approach
hexamer
prna
nanoparticl
offer
six
posit
avail
carri
molecul
cell
recognit
therapi
andor
detect
varieti
molecul
heavi
metal
quantum
dot
fluoresc
bead
radioisotop
also
conjug
detect
via
imag
cancer
signatur
differ
development
stage
therapeut
efficaci
could
improv
conjug
prna
endosmolyt
chemic
trigger
releas
internalis
therapeut
reagent
endosom
prna
nanocarri
could
also
use
treatment
chronic
viral
infect
target
specif
virusglycoprotein
surfac
virusinfect
cell
studi
prna
structur
shown
prna
contain
two
distinct
domain
fold
independ
first
domain
doublestrand
helic
domain
end
second
domain
intermolecular
bind
domain
previous
report
alter
primari
sequenc
region
helic
domain
affect
prna
structur
fold
provid
two
opposit
strand
remain
complementari
follow
section
focu
design
construct
monomer
prna
variou
cargo
molecul
build
block
dimer
trimer
hexamer
prna
nanoparticl
stabil
rna
oligo
extracellular
intracellular
environ
one
major
challeng
rnabas
therapi
exonucleas
degrad
occur
within
short
period
time
consequ
degrad
rna
longer
serv
therapeut
agent
diseas
tissu
addit
improv
stabil
sirna
chemic
modif
see
section
prna
carrier
provid
addit
protect
connect
end
foreign
rna
end
prna
expect
exonucleas
resist
circularli
permut
rna
like
make
stabl
linear
counterpart
take
also
account
doublestrand
helic
structur
sirna
possibl
prna
good
candid
carri
particular
sirna
sequenc
encod
helic
domain
test
hypothesi
wildtyp
nucleotid
sequenc
helic
domain
instead
encod
sirna
sequenc
target
gfp
luciferas
survivin
upon
transfect
specif
inhibit
target
gene
demonstr
mrna
protein
level
target
gene
silenc
test
use
two
chimer
prnasirna
construct
target
either
firefli
luciferas
renilla
luciferas
construct
found
silenc
luciferas
gene
express
without
show
nonspecif
inhibit
intern
control
luciferas
gene
express
knockdown
efficaci
chimer
prnasirna
compar
higher
chemic
synthesis
doublestrand
sirna
hairpin
sirna
gfp
express
survivin
necessari
downregul
gene
involv
tumour
develop
progress
suppress
chimer
prnasirna
survivin
prnaribozym
survivin
subsequ
cell
death
apoptosi
observ
abil
alter
nucleotid
sequenc
prna
combin
possibl
coupl
prna
end
variabl
sequenc
without
affect
fold
function
two
major
advantag
avail
method
use
circularli
permut
strategi
prnabas
vector
design
harbour
hammerhead
ribozym
end
hammerhead
ribozym
target
hbv
polya
signal
chimer
ribozym
flank
process
two
ciscleav
ribozym
abl
fold
correctli
escort
prna
cleav
polya
signal
hbv
mrna
vitro
almost
complet
inhibit
hbv
replic
prnaescort
ribozym
effici
absenc
prna
shown
northern
blot
hepat
b
eantigen
assay
cell
cultur
studi
prna
could
also
carri
anoth
hammerhead
ribozym
inhibit
differ
gene
thu
make
target
multipl
gene
possibl
state
section
prna
molecul
show
remark
fold
consist
even
sever
mutat
introduc
achiev
cellspecif
target
rna
aptam
identifi
use
construct
chimer
prnaaptam
via
mutual
end
connect
use
circular
permut
prna
vector
reorganis
nascent
reloc
residu
respect
origin
prna
sequenc
conceiv
prnarna
aptam
monom
construct
way
small
molecul
folat
cholesterol
conjug
prna
enabl
target
deliveri
specif
diseas
cell
folat
molecul
success
incorpor
prna
vitro
transcript
use
folateamp
altern
varieti
molecul
drug
chemic
imag
detect
endosom
disrupt
may
desir
deliv
target
cell
rna
chemistri
offer
simpl
method
conjug
deliveri
molecul
use
prnabas
vector
nucleic
acid
modifi
function
group
includ
nh
nh
coohand
sh
nhsreactiv
group
use
conjug
rna
molecul
primari
amin
group
nh
group
use
label
rna
molecul
contain
coohand
shgroup
via
carbodiimid
edc
varieti
amin
sulphydryl
reactiv
heterobifunct
crosslink
n
succinimid
ester
bmp
respect
shgroup
react
maleimid
deriv
chimer
prna
monom
carri
differ
cargo
molecul
specif
cell
recognit
imag
detect
therapeut
treatment
use
build
block
assembl
dimer
trimer
polyval
prna
deliveri
vehicl
assembl
mechan
dimer
trimer
prna
nanoparticl
base
interlock
loop
interact
prna
subunit
base
involv
interact
identifi
wildtyp
prna
leftand
righthand
loop
respect
sequenc
lefthand
loop
repres
capit
letter
sequenc
righthand
loop
repres
lowercas
letter
apostroph
lefthand
loop
one
monom
pair
righthand
loop
anoth
monom
vice
versa
case
two
gc
pair
interact
loop
suffici
allow
format
prna
dimer
howev
minimum
three
base
pair
need
prna
tertiari
interact
four
nucleotid
pair
least
one
gc
pair
requir
maximum
number
base
pair
requir
form
prna
multim
five
basepair
use
control
multipl
prna
nanoparticl
assembl
heteroor
homomultimer
structur
ration
design
interlock
basepair
allow
format
heteroor
homodim
trimer
exampl
prna
monom
loop
sequenc
form
homodim
meanwhil
homodim
howev
monom
incub
monom
dimeris
form
heterodim
capac
control
number
subunit
prna
nanoparticl
advantag
use
prnabas
vector
deliveri
multipl
therapeut
payload
control
stoichiometri
multival
prna
trimer
assembl
individu
chimer
prna
monom
design
specif
right
left
loop
interact
subunit
prna
fold
structur
compet
form
dimer
trimer
high
effici
confirm
gel
electrophoresi
afm
imag
sucros
gradient
sediment
dimer
trimer
prna
form
simpli
mix
individu
chimer
prna
complementari
partner
appropri
interlock
loop
group
design
trimer
prna
nanoparticl
harbour
three
individu
function
subunit
rna
aptam
receptorbind
ligand
specif
bind
cellsurfac
receptor
therapeut
agent
sirna
ribozym
antisens
rna
drug
deliv
report
molecul
fluoresc
tag
thu
prnabas
vector
enabl
simultan
applic
sirna
aptam
specif
receptor
track
deliveri
via
fluoresc
marker
allow
use
singl
cargo
carrier
target
deliveri
therapeut
agent
confirm
deliveri
previou
studi
demonstr
incub
prna
vector
contain
receptorbind
aptam
therapeut
sirna
result
bind
coentri
nanoparticl
cell
subsequ
modul
apoptosi
cancer
cell
leukaemia
model
lymphocyt
specif
suppress
tumorgen
cancer
cell
also
confirm
ex
vivo
anim
trial
note
due
high
shear
forc
blood
stream
dyn
cm
system
vivo
applic
prna
nanoparticl
must
care
consid
previou
prna
multim
studi
intact
prna
dimer
trimer
success
deliv
cancer
cell
howev
cancer
cell
shortli
incub
prna
trimer
ex
vivo
support
prna
nanocarri
system
vivo
multival
deliveri
system
quantit
result
need
show
prna
multim
stabl
high
shear
forc
environ
deliv
sirna
use
prna
dimer
prnabas
vector
small
particl
size
narrow
size
distribut
modifi
carri
targetspecif
ligand
ration
easili
design
control
carri
variou
cargo
molecul
uniqu
featur
make
prna
ideal
polyval
deliveri
vector
result
support
notion
prna
dimer
trimer
hexam
use
polyval
vehicl
deliveri
six
therapeut
molecul
specif
cell
ongo
research
aim
utilis
prnabas
vector
vivo
treatment
lung
cancer
brain
neck
cancer
ovari
cancer
breast
cancer
prostat
cancer
leukaemia
probe
specif
cell
bind
folateprnaprnasirna
survivin
dimer
complex
folatereceptor
posit
human
nasopharyng
epiderm
carcinoma
kb
cell
incub
dimer
prna
compris
folat
label
prna
monom
radiolabel
prna
monom
bind
dimer
prna
confirm
via
radioact
emiss
probe
success
deliveri
firefli
luciferas
gene
knockdown
also
achiev
simpl
cell
cultur
incub
dimer
prna
nanoparticl
contain
folatelabel
chimer
prnasirna
demonstr
specif
dimer
prna
harbour
folat
sirna
survivin
anim
trial
also
perform
athym
nude
mice
kb
cell
preincub
chimer
prna
complex
without
folat
sirna
survivin
axilla
inject
nude
mice
within
week
inject
mice
receiv
kb
cell
without
folateprna
prnasirna
survivin
develop
tumour
receiv
cancer
cell
pretreat
folateprna
prnasirna
survivin
specif
tumour
inhibit
probe
use
prnaderiv
vector
without
folat
contain
mutat
survivin
sirna
sequenc
show
effect
tumour
develop
mice
group
rna
chemistri
use
conjug
folat
prna
easili
extend
target
report
molecul
artifici
cell
line
dimer
made
prna
sirna
survivin
aptam
select
effici
deliv
dimer
cell
subsequ
sirna
knockdown
kill
cell
cancer
cell
express
affect
treatment
demonstr
activ
depend
work
done
vitro
artifici
clinic
nonrelev
target
receptor
howev
clearli
illustr
promis
prnabas
vector
proteinfre
nanos
target
sirna
deliveri
approach
demonstr
success
bind
entri
multival
prna
complex
cell
prna
trimer
construct
use
aptam
prna
fluoresc
label
fluorescein
fitc
rhodamin
rho
respect
bind
entri
trimer
visualis
use
confoc
microscopi
dual
channel
detect
two
emiss
wavelength
indic
prna
prna
conjug
codeliv
cell
specif
bind
cell
demonstr
fluoresc
emiss
origin
cell
surfac
could
detect
cell
lack
entri
trimer
cell
via
endocytosi
visibl
fluoresc
spot
localis
within
cell
result
strongli
support
idea
prna
trimer
serv
vehicl
target
deliveri
multipl
therapeut
compon
dnaand
proteinbas
technolog
extens
explor
nanotechnolog
tissu
engin
applic
howev
rna
gener
prna
particular
last
decad
brought
attent
good
candid
purpos
rna
combin
abil
easili
design
manipul
differ
construct
specif
dna
nanotechnolog
robust
versatil
structur
characterist
protein
work
demonstr
prna
engin
assembl
number
differ
structur
shape
includ
dimer
twin
trimer
tetram
rod
triangl
hexam
array
ten
micron
size
construct
contain
thousand
prna
build
block
array
collect
mani
subunit
join
togeth
repeat
pattern
form
largescal
structur
array
stabl
wide
rang
temperatur
salt
concentr
ph
level
protein
compon
dnapackag
motor
also
use
construct
array
engin
serv
chip
diagnosi
diseas
function
ultrahigh
densiti
data
storag
system
order
biolog
structur
array
serv
templat
construct
superlattic
anoth
applic
rna
array
would
antigenicityfre
biodegrad
scaffold
wound
tissu
repair
tissu
engin
novel
order
structur
assembl
protein
prna
also
convert
metal
array
replica
metal
spray
coat
technolog
potenti
applic
array
includ
molecular
siev
scaffold
largescal
supramolecular
structur
nanowir
nanochip
detect
pathogen
ultrahigh
densiti
data
storag
system
although
sirna
hold
great
potenti
clinic
drug
silenc
diseasecaus
gene
recent
research
discov
sever
undesir
side
effect
associ
sirna
mechan
side
effect
rang
sequenceindepend
effect
choic
vector
ie
viral
nonvir
deliveri
side
effect
similar
identifi
clinic
develop
therapeut
antisens
oligonucleotid
vertebr
immun
respons
induc
dsrna
mechan
defend
viral
infect
dsrna
sens
cytoplasm
endosom
compart
rnadepend
kinas
pkr
activ
pkr
induc
interferon
ifn
respons
lead
global
inhibit
protein
synthesi
phosphoryl
product
proinflammatori
cytokin
activ
nfkappab
besid
pkr
recent
studi
show
dsrna
within
cytoplasm
also
sens
helicas
retinoidacidinduc
gene
rigi
melanoma
differentiationassoci
gene
may
also
contribut
activ
nfkappab
product
ifn
rigi
intracellular
pathogenrecognit
receptor
varieti
virus
recognis
rigi
trigger
innat
antivir
respons
independ
tolllik
receptor
tlr
depend
pathway
gene
induc
differenti
cancer
revers
cell
apoptosi
past
long
dsrna
bp
consid
induc
interferon
respons
howev
studi
found
chemic
synthesis
sirna
gener
vitro
transcript
variou
length
lead
activ
pkr
longer
length
dsrna
stronger
effect
host
cell
studi
perform
rossi
group
report
triphosph
polymerasetranscrib
rna
molecul
potent
induc
ifn
respons
addit
sens
within
cell
nonself
rna
recognis
cell
surfac
tlr
varieti
tlr
express
immun
cell
identifi
nonself
pattern
pathogen
among
recognis
viral
synthet
singlestrand
rna
ssrna
contain
gurich
sequenc
believ
recognis
dsrna
polyipolyc
sequenc
recognit
rna
tlr
activ
cellularsignal
pathway
lead
activ
nfkb
product
proinflammatori
cytokin
recent
studi
shown
sirna
vegf
eye
trigger
cell
surfac
vegf
proangiogen
factor
involv
agerel
macular
degener
although
intend
effect
ie
decreas
blood
vessel
growth
observ
effect
seen
regardless
sequenc
exampl
sirnatarget
luciferas
also
show
reduc
vessel
growth
silenc
attribut
sequenceindepend
trigger
subsequ
cytotox
therefor
tlr
repres
anoth
import
compon
sirnamedi
immun
respons
avoid
reduc
unfavour
immun
respons
sirna
need
optimis
avoid
gurich
sequenc
pattern
may
trigger
tlr
respons
optimis
length
andor
reduc
dose
sirna
may
also
help
allevi
ifn
respons
final
experiment
screen
multipl
sirna
target
requir
identifi
candid
minim
immun
respons
offtarget
effect
sirna
refer
undesir
silenc
gene
intend
target
offtarget
silenc
subject
intens
studi
may
lead
seriou
unpredict
side
effect
typic
sirna
induc
immun
respons
sequenceindepend
manner
mention
section
sirnamedi
induct
immun
respons
affect
global
rna
transcript
protein
synthesi
hand
sequencedepend
offtarget
effect
come
presenc
sequenc
sirna
partial
match
mrna
sequenc
nontarget
gene
host
exist
homolog
sequenc
lead
cleavag
nontarget
mrna
inhibit
translat
similar
fashion
action
mirna
use
bioinformat
care
comparison
sequenc
sirna
host
genom
necessari
exclud
possibl
match
sequenc
recent
studi
found
modif
posit
guidestrand
sirna
reduc
offtarget
silenc
transcript
complementari
seed
region
sirna
guid
strand
howev
unlik
success
avoid
sequencedepend
offtarget
effect
current
sirna
design
algorithm
highthroughput
mrna
protein
array
use
determin
gene
affect
sirna
help
evalu
offtarget
effect
individu
sirna
candid
fundament
studi
indic
high
level
shrna
precursor
molecul
sirna
express
adenoassoci
viru
type
caus
sever
liver
toxic
mortal
mice
hepatocyt
toxic
associ
satur
endogen
mirna
pathway
machineri
process
transport
mirna
nuclear
karyopherin
satur
excess
exogen
shrna
resembl
mirna
studi
hint
potenti
danger
use
viral
vector
sirna
deliveri
addit
risk
disrupt
endogen
small
rna
pathway
minimis
optimis
length
shrna
reduc
dose
viru
optimis
shrna
express
level
also
achiev
use
differ
promot
transcript
besid
challeng
specif
deliveri
challeng
sirna
therapi
nonspecif
gene
silenc
immun
respons
cytotox
current
area
extens
investig
feasibl
solut
question
emerg
nonspecif
gene
silenc
offtarget
effect
reduc
altern
sirna
size
target
locat
modifi
primari
sequenc
sens
strand
toler
sequenc
modif
without
lose
genesilenc
potenti
immun
respons
sirna
includ
pkr
effect
tolllik
immun
dsrnainduc
interfer
induct
alphabeta
interferon
reader
direct
recent
excel
review
area
ideal
system
deliveri
vector
nm
size
nontox
nonimmunogen
stabl
capabl
effici
intracellular
deliveri
possess
specif
target
abil
one
key
reason
antibodi
therapi
current
mani
problem
clinic
scientist
look
new
solut
nanotechnolog
rna
engin
nanotechnolog
emerg
novel
excit
area
therapi
diagnosi
diseas
among
therapeut
rna
categori
sirna
arguabl
elicit
excit
make
applic
therapeut
sirna
realiti
futur
research
must
continu
focu
achiev
effici
deliveri
desir
cell
minimis
offtarget
effect
increas
resist
nucleas
degrad
avoid
immun
respons
interferon
pkr
effect
tolllik
immun
trap
polymeris
particl
kuffer
cell
lung
macrophag
